Literature DB >> 2317751

Simultaneous versus sequential combined technique therapy for squamous cell head and neck cancer.

D J Adelstein1, V M Sharan, A S Earle, A C Shah, C Vlastou, C D Haria, C Damm, S G Carter, J D Hines.   

Abstract

Forty-eight patients with locally confined (M0) squamous cell head and neck cancer were prospectively randomized to receive either simultaneous (SIM) or sequential (SEQ) combined technique therapy with a 5-fluorouracil infusion, a cisplatin bolus injection, and radiation therapy. Patients with residual resectable disease underwent surgery after induction therapy, whereas those achieving a complete response to induction did not require surgery. Patients on the two treatment arms were equivalent in all measured variables, including disease extent. Toxicities of the SIM and SEQ arms also were equivalent except for mucositis and the resultant weight loss, which were more severe on the SIM arm (P = 0.002). With a follow-up time ranging from 9 to 41 months, seven of the 24 SIM patients and 14 of the 24 SEQ patients are considered treatment failures. The relapse-free survival is significantly better on the SIM arm (P = 0.03), although an overall survival advantage has not yet been demonstrated (P = 0.13). The achievement of a complete response after induction therapy correlates with both the relapse-free (P = 0.0005) and overall (P = 0.05) survival, and the likelihood of an induction complete response also is significantly better for those treated with the SIM schedule (P = 0.02). Eighteen patients did not require surgery after achieving an induction complete response. Relapse-free survival does not appear to be compromised in this patient subset.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2317751     DOI: 10.1002/1097-0142(19900415)65:8<1685::aid-cncr2820650804>3.0.co;2-s

Source DB:  PubMed          Journal:  Cancer        ISSN: 0008-543X            Impact factor:   6.860


  8 in total

1.  Organ preservation in locally advanced head and neck cancer of the larynx using induction chemotherapy followed by improved radiation schemes.

Authors:  Giovanni Franchin; Emanuela Vaccher; Doriano Politi; Emilio Minatel; Carlo Gobitti; Renato Talamini; Simon Spazzapan; Maria Gabriella Savignano; Mauro G Trovò; Luigi Barzan
Journal:  Eur Arch Otorhinolaryngol       Date:  2008-09-09       Impact factor: 2.503

2.  Cisplatin Every 3 Weeks Versus Weekly With Definitive Concurrent Radiotherapy for Squamous Cell Carcinoma of the Head and Neck.

Authors:  Joshua M Bauml; Ravi Vinnakota; Yeun-Hee Anna Park; Susan E Bates; Tito Fojo; Charu Aggarwal; Sewanti Limaye; Nevena Damjanov; Jessica Di Stefano; Christine Ciunci; Eric M Genden; Juan P Wisnivesky; Rocco Ferrandino; Ronac Mamtani; Corey J Langer; Roger B Cohen; Keith Sigel
Journal:  J Natl Cancer Inst       Date:  2019-05-01       Impact factor: 13.506

3.  Cytokinetic effects of cisplatin on diverse human head and neck carcinomas in vitro: dependence on the tumor sensitivity to cisplatin.

Authors:  M C Jäckel; R Tausch-Treml; P Köpf-Maier
Journal:  J Cancer Res Clin Oncol       Date:  1996       Impact factor: 4.553

Review 4.  Head and neck cancer: guidelines for chemotherapy.

Authors:  G Catimel
Journal:  Drugs       Date:  1996-01       Impact factor: 9.546

Review 5.  Interventions for the treatment of oral cavity and oropharyngeal cancer: chemotherapy.

Authors:  Ambika Parmar; Michaelina Macluskey; Niall Mc Goldrick; David I Conway; Anne-Marie Glenny; Janet E Clarkson; Helen V Worthington; Kelvin Kw Chan
Journal:  Cochrane Database Syst Rev       Date:  2021-12-20

6.  Treatment results for hypopharyngeal cancer by different treatment strategies and its secondary primary--an experience in Taiwan.

Authors:  Morgan Fu-Ti Chang; Hung-Ming Wang; Chung-Jan Kang; Shiang-Fu Huang; Chien-Yu Lin; Kang-Hsing Fang; Eric Yen-Chao Chen; I-How Chen; Chun-Ta Liao; Joseph Tung-Chieh Chang
Journal:  Radiat Oncol       Date:  2010-10-07       Impact factor: 3.481

7.  Meta-analysis of chemotherapy in head and neck cancer (MACH-NC): An update on 107 randomized trials and 19,805 patients, on behalf of MACH-NC Group.

Authors:  Benjamin Lacas; Alexandra Carmel; Cécile Landais; Stuart J Wong; Lisa Licitra; Jeffrey S Tobias; Barbara Burtness; Maria Grazia Ghi; Ezra E W Cohen; Cai Grau; Gregory Wolf; Ricardo Hitt; Renzo Corvò; Volker Budach; Shaleen Kumar; Sarbani Ghosh Laskar; Jean-Jacques Mazeron; Lai-Ping Zhong; Werner Dobrowsky; Pirus Ghadjar; Carlo Fallai; Branko Zakotnik; Atul Sharma; René-Jean Bensadoun; Maria Grazia Ruo Redda; Séverine Racadot; George Fountzilas; David Brizel; Paolo Rovea; Athanassios Argiris; Zoltán Takácsi Nagy; Ju-Whei Lee; Catherine Fortpied; Jonathan Harris; Jean Bourhis; Anne Aupérin; Pierre Blanchard; Jean-Pierre Pignon
Journal:  Radiother Oncol       Date:  2021-01-27       Impact factor: 6.280

8.  A non-randomised, single-centre comparison of induction chemotherapy followed by radiochemotherapy versus concomitant chemotherapy with hyperfractionated radiotherapy in inoperable head and neck carcinomas.

Authors:  Reinhold Graf; Bert Hildebrandt; Wolfgang Tilly; Hanno Riess; Roland Felix; Volker Budach; Peter Wust
Journal:  BMC Cancer       Date:  2006-02-01       Impact factor: 4.430

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.